Relyvrio (sodium phenylbutyrate and taurursodiol), an approved treatment for amyotrophic lateral sclerosis (ALS), was voluntarily removed from the…
Articles by Steve Bryson, PhD
More than a third of people diagnosed with amyotrophic lateral sclerosis (ALS) also showed signs of…
AcuraStem has secured nearly $7 million in grant funding from the National Institutes of Health (NIH)…
Cigarette smoking, either currently or in the past, significantly increases the likelihood of developing amyotrophic lateral sclerosis (ALS), particularly…
The ALS Society of Canada (ALS Canada) has awarded two expedited grants totaling $200,000 to international researchers seeking to…
A European Medicines Agency (EMA) committee again has delayed issuing an opinion on whether to grant conditional approval to…
The proportion of people diagnosed with familial amyotrophic lateral sclerosis (ALS) among all cases is 8%, according to a…
A previously unknown mutation in the SPTLC2 gene was identified in two patients who developed juvenile-onset amyotrophic lateral sclerosis…
Throughout 2023, ALS News Today brought you daily coverage of the latest clinical research and scientific breakthroughs related to…
Early data from Phase 2 programs showing that CNM-Au8, an oral therapy candidate for amyotrophic lateral sclerosis (ALS),…